RxDoctor Payments Data

Michael Rahmin, MD

Gastroenterology · Ridgewood, NJNPI 1902856313

Payments from drug & device makers

$7,093in general payments, 2019–2025

Across 74 payments — averaging $95.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$3K
  • Amgen$3K
  • AbbVie$260
  • Bristol Myers Squibb$186
  • Johnson & Johnson$156
  • Gilead$121
  • plus $486 from 11 others
$1,219in research payments, 2019–2025

Across 1 payment — averaging $1218.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Consulting fees$5,80082%
  • Speaking & faculty fees$501%
  • Food & beverage$1,14716%
  • Education$961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,093 in reported general payments places this provider in the 75th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$344,988
Medicare patients
1,076
Services billed
2,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase54$134,772
XifaxanRifaximin20$42,327
Mesalamine53$38,805
LinzessLinaclotide44$34,710
DipentumOlsalazine Sodium12$19,850
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates298$19,720
VemlidyTenofovir Alafenamide11$15,836
TrulancePlecanatide13$13,764
Sucralfate86$13,303
Omeprazole597$10,322
NexiumEsomeprazole Magnesium16$10,088
ClenpiqSod Picosulf/Mag Ox/Citric Ac57$9,754
Famotidine405$5,626
Pantoprazole Sodium308$5,166
Mesalamine DrMesalamine12$4,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$260$169,48298 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$75$56,09133 claims
GileadVemlidy$121$15,83611 claims
Braintree Laboratories, Inc.Sutab$26$2,41915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Ridgewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →